Laberon

Beclometasone dipropionate, the active ingredient in Laberon, is a combination corticosteroid and long‑acting β2‑agonist presented as an inhalation formulation for inhalation use. It treats asthma and chronic obstructive pulmonary disease (COPD) in adults and children as prescribed.

GNH USA supplies Laberon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Laberon is a combination inhaled corticosteroid and long‑acting β2‑agonist used to manage chronic airway diseases. - Asthma: improves symptom control and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): enhances lung function and decreases dyspnoea during daily activities. - Exercise‑induced bronchoconstriction (in patients with asthma): provides prophylactic bronchodilation to maintain airway patency during physical activity.

Laberon may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Throat irritation or soreness. - Hoarseness of voice. - Oral candidiasis (thrush). - Headache.

Serious or Rare Side Effects: - Paradoxical bronchospasm. - Adrenal suppression with prolonged high‑dose use. - Severe allergic reactions such as anaphylaxis. - Cardiac arrhythmias or tachycardia. - Pneumonia, particularly in patients with COPD.

Before prescribing Laberon, clinicians should consider several safety aspects. - Infection risk: monitor for signs of respiratory infection, especially in COPD patients. - Growth monitoring: assess growth velocity in children receiving long‑term therapy. - Discontinuation: avoid abrupt cessation; taper if high‑dose corticosteroid therapy is used. - Administration technique: advise use of a spacer and mouth‑rinse after inhalation to reduce local effects. - Concomitant steroids: limit total systemic corticosteroid exposure. - Store at room temperature: keep in the original container, protect from moisture and direct heat.

Laberon can interact with other medicines that affect cardiovascular or steroid pathways.

Major Interactions (Avoid): - Non‑selective β‑blockers: may diminish bronchodilator response and precipitate bronchospasm. - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): can increase systemic exposure to beclometasone.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance the risk of hypokalaemia when combined with β2‑agonists. - Other inhaled or systemic corticosteroids: increase risk of systemic steroid effects. - Monoamine oxidase inhibitors (MAOIs): may potentiate cardiovascular effects of formoterol. - Anticholinergic bronchodilators: monitor for additive bronchodilation and potential tachycardia.